Session Type
Meeting
Search Results for Methylnaltrexone
Abstract Number: 59
SHM Converge 2021
Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC), which can be a serious consequence of opioid analgesia. We evaluated whether baseline osmotic agent (eg, milk of magnesia, polyethylene glycol, lactulose, sorbitol) or stimulant (eg, senna, bisacodyl) use affects the efficacy and safety of MNTX among a subgroup of […]
Abstract Number: G6
SHM Converge 2022
Background: Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC). We evaluated whether baseline use of laxatives, including stimulants, osmotic agents, stool softeners, or combinations thereof affects the efficacy and safety of MNTX. Methods: This post hoc analysis included pooled data from 2 multicenter, randomized, double-blind, placebo (PBO)-controlled, institutional review […]
Abstract Number: 180
SHM Converge 2023
Background: Almost three-quarters of hospitals with 50 or more beds have a palliative care program, and the percentage of annual hospital admissions receiving an initial palliative care consultation is more than 5%. Methylnaltrexone (MNTX) is a peripherally acting µ-opioid receptor antagonist indicated for opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative […]
Abstract Number: 434
Hospital Medicine 2019, March 24-27, National Harbor, Md.
Background: Subcutaneous (SC) methylnaltrexone (MNTX) is approved for opioid-induced constipation (OIC) in adults with chronic noncancer pain and OIC in adults with advanced illness or with active cancer who require opioid dosage escalation for palliative care. This post hoc analysis evaluated data pooled from 3 randomized studies of patients with advanced illness and OIC. Methods: […]
Abstract Number: I11
SHM Converge 2022
Background: Opioid analgesia is an important treatment modality for patients with chronic pain, including pain attributed to cancer- and noncancer-related illness. Unfortunately, an estimated 40%–80% of opioid users experience opioid-induced constipation (OIC). Methylnaltrexone (MNTX) is indicated for the treatment of OIC. In clinical trials, the most common adverse events (AEs) were gastrointestinal (GI) in nature. […]
Abstract Number: 1062
Hospital Medicine 2020, Virtual Competition
Case Presentation: We present the case of a 58 -year-old opioid naïve man admitted for elective knee arthroplasty received parenteral hydromorphone and enteral oxycodone for analgesia. On post-operative day one, he developed abdominal pain. Abdominal X-ray showed stool burden suggesting constipation (OIC) prompting management with laxatives; he was given 12 mg parenteral methylnaltrexone. Overnight he […]